ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact

Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact
Literature review current through: May 2024.
This topic last updated: May 29, 2024.

INTRODUCTION — Similar to eutopic endometrial tissue, endometriosis lesions contain endometrial glands and stroma but occur outside the uterine cavity. The lesions are typically located in the pelvis but can occur at multiple sites including the bowel, diaphragm, and pleural cavity. While endometriosis is a common and nonmalignant process, ectopic endometrium-like tissue and resultant inflammation can cause dysmenorrhea, dyspareunia, chronic pain, and infertility. Symptoms can range from minimal to severely debilitating. Endometriosis is an estrogen-dependent, benign, inflammatory disease that affects females during their premenarcheal, reproductive, and postmenopausal hormonal stages.

This topic will review the clinical presentation and diagnosis of endometriosis. Information on the treatment of endometriosis is presented separately.

(See "Endometriosis: Treatment of pelvic pain".)

(See "Endometriosis: Surgical management of pelvic pain".)

(See "Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists".)

In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.

HISTOLOGY AND LESION PHENOTYPES

Histology — Similar to eutopic endometrial tissue, endometriotic lesions contain endometrial glands and stroma (picture 1) [1]. Unlike eutopic endometrium, endometriotic implants exist outside of the uterine endometrium and myometrium and often contain fibrous tissue, blood, and cysts. Breakdown of red blood cells by inflammatory cells results in formation of pigmented histiocytes and hemosiderin-laden macrophages; the older the lesion, the more likely it is to be pigmented [2].

Lesion phenotypes — Endometriosis lesions in the pelvis can be categorized as superficial peritoneal, ovarian, and deep [1,3,4].

Superficial peritoneal – While superficial peritoneal lesions classically contain endometrial glands and stroma, diagnostic challenges arise when there are alterations or absence of glandular or stromal components [5]. The glandular component can be absent, sparse, or transformed by hormonal and metaplastic changes or cellular atypia. The stromal component can be obscured by infiltrates of foamy and pigmented histiocytes, fibrosis, or other processes. Inflammatory and reactive changes within or adjacent to foci of endometriosis can also confuse the histologic findings. Histologic diagnosis can also be hindered by a small biopsy sample.

Ovarian endometrioma – An ovarian endometrioma occurs when endometrium-like tissue forms an ovarian cyst [1]; ectopic endometrial tissue within the ovary bleeds and results in a collection of menstrual debris surrounded by duplicated ovarian parenchyma [6]. Both ovaries are involved in one-third of cases.

Typical findings – In contrast with most hemorrhagic physiologic ovarian cysts, endometriomas typically have fibrotic walls and surface adhesions; are filled with syrup-like chocolate-colored material; are surrounded by duplicated ovarian parenchyma [3]; and are lined by endometrial epithelium, stroma, and glands [7].

Cellular transformation – Epithelial abnormalities, such as complex hyperplasia or atypia, can develop in the cyst lining; the clinical significance of these changes has not been determined [8-12]. The endometrial epithelium and stroma lining the endometrioma can be lost over time and replaced by granulation tissue and dense fibrous tissue, which makes histological diagnosis difficult. In these cases, the contents of the cyst (semifluid chocolate-colored material versus watery fluid), presence of adhesions and hemosiderin-filled macrophages (indicative of chronic bleeding), and histologically proven endometriosis at other sites in the pelvis aid the diagnosis.

Management of ovarian endometriomas is presented separately. (See "Endometriosis: Management of ovarian endometriomas".)

Deep endometriosis – Deep endometriosis (DE) is endometrium-like tissue in the abdomen that extends under the peritoneum [1]. Some definitions include depth more than 5 mm deep to the peritoneum [13]. DE is generally found in the retrovaginal septum (also referred to as the rectocervical septum), rectum, rectosigmoid colon, bladder, ureter, and other pelvic fibromuscular structures such as the uterine ligaments and vagina [14].

(See "Endometriosis: Clinical manifestations and diagnosis of rectovaginal or bowel disease".)

(See "Endometriosis of the bladder and ureter".)

ANATOMY AND STAGING

Common pelvic sites – In general, the most common sites of endometriosis, in decreasing order of frequency, are [15,16]:

Ovary and ovarian fossa – 67 and 32 percent [17]

Anterior and posterior cul-de-sac

Posterior broad ligaments

Uterosacral ligaments – 46 percent [17]

Pouch of Douglas – 30 percent [17]

Bladder – 21 percent [17]

Uterus

Fallopian tubes

Sigmoid colon

Appendix

Round ligaments

Other – vagina, cervix, rectovaginal (or retrovaginal) septum, cecum, ileum, inguinal canals, perineal scars, ureters, and umbilicus [18-20]

Extra-pelvic sites – Occasionally, an endometrioma arises in the anterior abdominal wall, usually in the vicinity of a surgical incision [21-23], or umbilicus, although these lesions can occur in individuals with no history of surgery or history of endometriosis. Rarely, endometriosis has been reported in the breast, pancreas, liver, gallbladder, kidney, urethra, extremities, vertebrae, bone, peripheral nerves, spleen, diaphragm, central nervous system, hymen [24], and lung [25]. (See "Thoracic endometriosis: Pathogenesis, epidemiology, and pathology".)

Surgical staging – Endometriosis is surgically staged according to the revised American Society for Reproductive Medicine scoring system (form 1 and figure 1) [26], but other staging systems exist [27-29]. (See "Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Surgical staging of disease'.)

PATHOGENESIS — While many theories have been proposed to explain the etiology, no single theory explains all cases and all the theories help to explain some aspects of the disease. It is likely that the cause of endometriosis is multifactorial, with contributions from several of the proposed mechanisms.

Pathogenesis and genetics – Endometriosis results when ectopic endometrial cells implant, grow, and elicit an inflammatory response [30]. The pathogenesis of endometriosis appears to be multifactorial, including transportation from the uterus to the peritoneal cavity of ectopic endometrial tissue, altered immunity, imbalanced cell proliferation and apoptosis, aberrant endocrine signaling, and genetic factors. Genetic studies, including genome-wide association studies and exome sequencing, have identified genomic regions and abnormalities in cancer driver genes (PIK3CA, KRAS, ARID1A) associated with endometriosis [31-33]. The presence of cancer driver mutations in nonmalignant cells may partly explain the aggressive nature of deeply invasive lesions compared with superficial peritoneal lesions.

Theories of endometriosis development – There are multiple proposed theories to explain the development of endometriosis; these may work in concert to create the clinical disease.

Retrograde menstruation – In the most common theory of ectopic endometrial cells (Sampson's theory of retrograde menstruation), endometrial cells flow backwards through the fallopian tubes and into the peritoneal cavity during menses [34]. Evidence supporting retrograde menstruation comes from the observation that the incidence of endometriosis is increased in girls with genital tract obstructions that prevent drainage of menses through the vagina and therefore increase tubal reflux [35,36]. However, while up to 90 percent of females have retrograde menstruation [37], most do not develop endometriosis, which suggests that additional factors are involved [3].

Alternate mechanisms – Other potential sources of ectopic endometrial cells include mesothelium, stem cells, müllerian rests [38], bone marrow stem cells [38,39], and embryonic vestiges [40] as well as lymphatic or vascular dissemination [41,42] and coelomic metaplasia [43,44]. The cellular immunity theory suggests that a deficiency or aberration in cellular immunity allows ectopic endometrial tissue to proliferate [45-47].

Premenarcheal endometriosis – The existence of endometriosis in girls prior to menstruation, and thus not yet exposed to retrograde menstruation, challenges the retrograde menstruation hypothesis regarding the etiology of endometriosis. Possible explanations for premenarcheal endometriosis include the existence of müllerian embryonic rests [48], that these lesions are preexisting antecedents to the classic form of endometriosis [49], and that the lesions are the result of neonatal uterine bleeding, including retrograde bleeding, caused by maternal hormone exposure [50-53].

Mechanism of pain – Once endometriosis is established, the process appears to cause symptoms through inflammatory changes. Endometriosis-related pelvic pain is associated with increased production of inflammatory and pain mediators as well as neurologic dysfunction related to the implants [54-58]. An increase of nerve fibers [54,59] and imbalance of sympathetic and sensory nerve fibers [60,61] have been demonstrated in individuals with endometriosis-related pain. Proposed mechanisms for pain symptoms include estrogen acting as a neuromodulator that selectively repulses the sympathetic axons while preserving sensory innervation [62], inflammation stimulating peripheral nerve sensitization [63], and chronic pain inducing changes in the central nervous system [64].

Mechanism of subfertility – The mechanism for subfertility appears to involve anatomic distortion from pelvic adhesions and endometriomas and/or production of substances (eg, prostanoids, cytokines, growth factors) that are "hostile" to normal ovarian function/ovulation, sperm mobility, fertilization, and implantation. (See "Endometriosis: Treatment of infertility in females", section on 'Pathogenesis of infertility from endometriosis'.)

EPIDEMIOLOGY

Prevalence — Globally, it is estimated that approximately 10 percent of reproductive-age females have endometriosis [65-67]. Determining the prevalence of endometriosis in a general population is challenging because some individuals are asymptomatic, those with symptoms can have varied and nonspecific presentations, and definitive diagnosis typically requires surgery [68].

Reported prevalence ranges for different populations include [36,65-79]:

Asymptomatic individuals – 1 to 7 percent

Individuals undergoing hysterectomy for benign indications – 15 percent

Adolescents with genital tract anomalies – 40 percent

Females presenting with infertility – up to 50 percent

Adolescent and adult females presenting for evaluation of chronic pelvic pain – up to 70 percent

Risk factors

Increase risk – Established factors associated with an increased risk of endometriosis include family history [31,80], nulliparity [73,81,82], prolonged exposure to endogenous estrogen (eg, early menarche [before age 11 to 13 years] [30,83,84] or late menopause [30]), shorter menstrual cycles (defined as ≤27 days) [73], heavy menstrual bleeding [73], obstruction of menstrual outflow (eg, cervical stenosis, müllerian anomalies [30,85]), exposure to diethylstilbestrol in utero [86,87], taller height [81,88], and lower body mass index [73,81].

Reduce risk – Factors associated with a decreased risk of endometriosis include multiple births [85,89,90], extended intervals of lactation [89,91], and late menarche (after age 14 years) [83]. However, pregnancy should not be advised as a "treatment" for endometriosis [92].

CLINICAL IMPACT

Fertility — The impact of endometriosis on fertility is presented elsewhere. (See "Endometriosis: Treatment of infertility in females".)

Pregnancy

Course during pregnancy — During pregnancy, small peritoneal endometriosis lesions may undergo decidualization or regression, and the endometriosis-associated pain symptoms often improve [93]. In one prospective study, the risk of laparoscopically confirmed endometriosis decreased linearly as the number of liveborn children increased [85]. However, pregnancy is not a "treatment" for endometriosis and should not be advised to reduce pelvic pain. Suggesting such may negatively impact the patient-provider relationship [92].

Reported complications of endometriosis – Case reports have described complications caused by endometriosis in pregnant individuals, including intestinal perforation [94], hemoperitoneum [95-98], uroperitoneum [99,100], acute appendicitis [101,102], and ruptured or infected ovarian endometrioma [103]. As these events are rare overall, no routine monitoring or interventions are recommended for pregnant individuals with endometriosis unless new symptoms arise.

Possible mechanisms – Possible mechanisms of endometriosis-induced complications during pregnancy include traction by the growing uterus on adhesions, increased friability of inflamed tissues, and alteration of vessel walls by decidualized lesions (either intrusion or retraction) [103].

Obstetric outcomes — The body of evidence suggests endometriosis negatively impacts some pregnancy outcomes, particularly increasing the risk of preterm birth, although not all studies support this association [104-113]. Other reported outcomes include placenta previa, hemorrhage, and low birth weight [105,113,114]. The mechanism behind these associations is not known, and additional surveillance for pregnant individuals with known endometriosis is not advised [103].

Supporting data include:

Birth outcomes – A meta-analysis of 33 studies that included over 3 million pregnancies reported that, among those who conceived spontaneously, endometriosis was associated with placenta previa, cesarean delivery, preterm birth, and low birth weight [113].In two large retrospective population-based studies (including over 82,000 and 91,000 total births, respectively), individuals with endometriosis had an increased risk of preterm birth, preeclampsia, and cesarean birth when compared with individuals without endometriosis [104,111].  

Severe maternal morbidity – A retrospective cohort study including over 2.4 million deliveries in Quebec, Canada reported increased risk of severe maternal morbidity with any prior endometriosis (risk ratio [RR] 1.43, 95% CI 1.36-1.51) and active endometriosis (RR 1.93, 95% CI 1.76-2.11) compared with no endometriosis exposure [115].

Large studies support the findings of prior smaller studies that noted an increased risk of preterm birth [106-109] and pregnancy loss [108,116-118] in individuals with endometriosis. In contrast, older, smaller studies reported decreased or no change in risk of hypertensive disorders of pregnancy in patients with endometriosis [119,120]. These studies should be interpreted with caution because the presence of endometriosis and/or prior treatments was not known at the time of conception.

Postmenopause — Endometriosis may remain an active disease after menopause. Approximately 2 percent of all patients with an initial surgical diagnosis of endometriosis are postmenopausal based on data from older studies [121-123]. Severely symptomatic endometriosis is not common in postmenopause.

Potential etiologies and mechanisms – It is not known if postmenopausal endometriosis results from lesions established during the reproductive years or if postmenopausal endometriosis arises de novo. Symptomatic postmenopausal endometriosis occurs in those both on and off hormone therapy [124]. In a study of 72 women with symptomatic postmenopausal endometriosis, only two were using hormone therapy at the time of surgery [125].

Possible mechanisms of postmenopausal estrogen production include extra-ovarian estrogen production (eg, skin, fat tissue) and or lesion-specific production [126,127].

Treatment options – Treatment of symptomatic postmenopausal endometriosis must balance the potential risk of underlying malignancy as a cause of symptoms with the limited hormonal treatment options for this age group. (See "Endometriosis: Treatment of pelvic pain", section on 'Surgical treatment options'.)

Surgery – One society advises surgery as the first-line approach [124]. At least one case of postmenopausal endometriosis that required pelvic exenteration for treatment has been reported [128]. (See "Endometriosis: Treatment of pelvic pain", section on 'Surgical treatment options'.)

Medical therapy – Medical treatment options include nonsteroidal anti-inflammatory drugs, progestins, and aromatase inhibitors (AIs). The limited available data suggest that AI treatment can reduce symptoms but its use may be limited by side effects [129,130]. (See "Endometriosis: Treatment of pelvic pain", section on 'Medical treatment options'.)

Ovarian cancer risk

Summary – There appears to be an increased risk of ovarian cancer, particularly endometrioid and clear cell types, in individuals with ovarian endometriosis but not for patients with peritoneal or deeply infiltrating endometriosis [131]. It is unclear if the increased risk of ovarian cancer applies to superficial ovarian endometriosis lesions, endometriomas, or both. Some ovarian endometriosis lesions harbor genetic changes (mutations in ARID1A, PTEN, HNF1B and k-ras) that also may be found in ovarian cancer lesions. Future molecular analysis of surgical ovarian endometriosis specimens may help to identify patients at highest risk of developing ovarian cancer. While the relative risk of ovarian cancer may be increased, the absolute risk of developing ovarian cancer from ovarian endometriosis remains low, with approximately two additional cases per 10,000 women-years of follow-up for individuals with ovarian endometriosis compared with those without endometriosis [131].

Risk of transformation to cancer – The risk of malignant transformation of endometriosis has been estimated at 1 percent for premenopausal females [132] and 1 to 2.5 percent for postmenopausal females [133,134]. In a study of individuals with postmenopausal endometriosis, 35 percent (20 of 57) had different grades of metaplasia, hyperplasia, atypia, and endometrioid carcinoma arising in ovarian endometriosis [125].

Endometriosis appears to be associated with some epithelial ovarian cancers (EOCs) [135]; whether those with endometriosis are at risk for other types of cancers is unclear, but the overall risk appears to be low [136-138]. In a meta-analysis of 13 case-control studies including nearly 8000 women with EOC, those with a self-reported history of endometriosis had three times the risk of clear cell EOC and double the risk of endometrioid and low-grade serous EOC but no change in risk of high-grade serous or mucinous EOC [139]. A subsequent population-based study of nearly 50,000 Finnish women with endometriosis again reported an overall increased risk of ovarian cancer (endometrioid, clear cell, and serous types) in individuals with ovarian endometriomas (ie, ovarian endometriosis; overall standardized incidence ratio [sIR] 2.56, 95% CI 1.98-3.27), but not for those with peritoneal or deep infiltrating endometriosis [131]. The excess risk of ovarian cancer for patients with ovarian endometriosis resulted in two additional cases per 1000 women followed for 10 years. In this study, there was no statistically significant association with isolated peritoneal endometriosis and ovarian cancer.

Increased risk of ovarian cancer – Supporting evidence comes from a Finnish database study including 49,933 women with a surgical diagnosis of endometriosis identified between 1987 and 2012 that included 838,685 women-years of follow-up [131].

Impact of any endometriosis – A surgical diagnosis of endometriosis was associated with a significantly increased risk of developing ovarian cancer (all types) compared with self-reported women without endometriosis (sIR 1.76, 95% CI 1.47-2.08) [131]. The greatest increases in risk were seen with endometrioid ovarian cancer (sIR 3.12, 95% CI 2.15-4.38) and clear cell ovarian cancer (sIR 5.17, 95% CI 3.20-7.89).

Impact of ovarian endometriosis – Ovarian endometriosis was associated with an increased risk of ovarian cancer (standardized incidence ratio [sIR] 2.56, 95% CI 1.98-3.27), with a higher risk reported for clear cell (sIR 10.1, 95% CI 5.5-16.9) and endometrioid (sIR 4.72, 95% CI 2.75-7.56) ovarian cancers [131].

Lack of risk with isolated peritoneal endometriosis – Isolated peritoneal endometriosis was associated with a slightly increased risk of ovarian cancer that did not reach statistical significance (sIR 1.32, 95% CI 0.99-1.72) [131].

No impact on uterine cancer – Surgically documented endometriosis was not associated with development of corpus uteri cancer (sIR 1.04, 95% CI 0.80-1.32) [131].

Prognosis if ovarian cancer develops – Endometriosis-associated EOC appears to develop in younger women and has a better prognosis than most cases of EOC [140,141]. In one retrospective series of 84 women with clear cell EOC, those with carcinoma arising in endometriosis lesions were younger (49 versus 59 years old) and had a better medial overall survival (196 versus 34 months) than patients without endometriosis [142]. (See "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum", section on 'Prognosis'.)

Proposed mechanisms of malignant transformation – Activation of oncogenic KRAS and PI3K pathways and inactivation of tumor suppressor genes PTEN and ARID1A have been suggested as mechanisms for the transformation of endometriosis, particularly ovarian endometriomas, to malignancy [135]. (See "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum", section on 'Histopathology and pathogenesis'.)

Ovarian cancer surveillance not advised – While there appears to be an association between endometriosis and EOCs, endometriosis is not considered a premalignant lesion and surveillance for ovarian cancer is not recommended. There are no high-quality data indicating that prophylactic removal of endometriosis lesions reduces the risk of EOC. However, use of oral contraceptive pills decreases the risk of ovarian cancer in all users.

(See "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis".)

(See "Screening for ovarian cancer".)

Cardiovascular disease — A possible association between atherosclerosis and endometriosis is supported by studies reporting a proatherogenic profile [143,144] and increased subclinical atherosclerosis [145] in patients with endometriosis. Studies of individuals with endometriosis reported increased risk of cardiovascular disease, including risk of myocardial infarction, composite cardiovascular disease, ischemic stroke, and all-cause mortality [146-148].

In the prospective Nurses' Health Study (NHS) II, among 116,430 women enrolled in 1989, 5296 reported laparoscopically confirmed endometriosis. In follow-up through 2009, there were 1438 incident cases of coronary heart disease (CHD). The risk of combined CHD endpoints was increased in those with endometriosis (risk ratio 1.62, 95% CI 1.39-1.89). Among the study participants with endometriosis, compared with not having a hysterectomy, having had a hysterectomy/oophorectomy was associated with an increased risk of CHD (1.51, 95% CI 1.34-1.71). A related study for NHS II also reported increased risk of stroke (multivariable-adjusted hazard ratio 1.34, 95% CI 1.10-1.62), of which nearly 40 percent was attributed to the impact of prior hysterectomy/oophorectomy [149]. More data are needed on the risk of CHD in those with endometriosis and potential benefits of CHD screening for these individuals.

Depression and anxiety — Similar to other chronic pelvic pain disorders, endometriosis has been associated with increased risks of depression and anxiety [150,151]. While the prevailing thought has been that the symptoms of pain and infertility negatively impact mental health [152], a genome-wide association study (GWAS) raised the possibility of a common genetic pathway [153]. A subsequent GWAS including over 8200 patients with endometriosis identified one gene locus, DGKB4212666606, with evidence of pleiotropy between endometriosis and depression [154]. Pleiotropy occurs when a genetic variant impacts multiple traits or has multiple biologic effects. (See "Mendelian randomization" and "Mendelian randomization", section on 'Pleiotropy'.)

RESOURCES FOR PATIENTS AND CLINICIANS

www.endometriosis.org – A nonprofit website dedicated to information about endometriosis and treatment.

European Society of Human Reproduction and Embryology Guideline: Endometriosis – Includes patient information in multiple languages as well as management guidelines for clinicians.

American College of Obstetricians and Gynecologists – Frequently asked questions about endometriosis.

Center for Young Women's Health – An informational site sponsored by Boston Children's Hospital.

American Society for Reproductive Medicine – Provides free materials on reproductive health issues for patients.

The Endometriosis Association – An independent, nonprofit, self-help organization of individuals with endometriosis, clinicians, and others interested in the disease.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Endometriosis".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient education: Endometriosis (The Basics)")

Beyond the Basics topic (see "Patient education: Endometriosis (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Histology and lesion phenotypes – Endometriosis lesions contain endometrial glands and stroma (picture 1). Unlike eutopic endometrium, endometriosis implants exist outside of the uterine endometrium and myometrium and often involve fibrous tissue, blood, and cysts. Pelvic endometriosis lesions can be categorized as superficial peritoneal, ovarian, and deep. The gross appearance and size of the implants vary. (See 'Histology and lesion phenotypes' above.)

Anatomy and staging – Common pelvic sites of endometriosis include the ovary and ovarian fossa, uterosacral ligaments, pouch of Douglas, and bladder. Endometriosis is staged at the time of surgery; the revised American Society for Reproductive Medicine scoring system is commonly used (form 1 and figure 1). (See 'Anatomy and staging' above.)

Pathogenesis – The pathogenesis of endometriosis has not been definitively established and appears to be multifactorial, including ectopic endometrial tissue, altered immunity, imbalanced cell proliferation and apoptosis, aberrant endocrine signaling, and genetic factors. (See 'Pathogenesis' above.)

Epidemiology – Globally, it is estimated that approximately 10 percent of reproductive-age females have endometriosis; prevalence varies by clinical population. Determining the prevalence of endometriosis is challenging because some individuals are asymptomatic, those with symptoms can have varied and nonspecific presentations, and definitive diagnosis typically requires surgery. (See 'Epidemiology' above.)

Impact of endometriosis other clinical conditions – Endometriosis has been associated with an increased risk of poor pregnancy outcomes, epithelial ovarian cancer (EOC), and atherosclerosis. More data are needed before changes in screening or patient care are made. (See 'Clinical impact' above.)

  1. International working group of AAGL, ESGE, ESHRE and WES, Tomassetti C, Johnson NP, et al. An International Terminology for Endometriosis, 2021. J Minim Invasive Gynecol 2021; 28:1849.
  2. Jansen RP, Russell P. Nonpigmented endometriosis: clinical, laparoscopic, and pathologic definition. Am J Obstet Gynecol 1986; 155:1154.
  3. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2014; 10:261.
  4. Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 1997; 68:585.
  5. Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 2007; 14:241.
  6. Brosens IA, Puttemans PJ, Deprest J. The endoscopic localization of endometrial implants in the ovarian chocolate cyst. Fertil Steril 1994; 61:1034.
  7. Muzii L, Bianchi A, Bellati F, et al. Histologic analysis of endometriomas: what the surgeon needs to know. Fertil Steril 2007; 87:362.
  8. Prefumo F, Todeschini F, Fulcheri E, Venturini PL. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 2002; 84:280.
  9. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979; 53:318.
  10. Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77:298.
  11. Seidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 1996; 15:1.
  12. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997; 30:249.
  13. De Cicco C, Corona R, Schonman R, et al. Bowel resection for deep endometriosis: a systematic review. BJOG 2011; 118:285.
  14. Woodward PJ, Sohaey R, Mezzetti TP Jr. Endometriosis: radiologic-pathologic correlation. Radiographics 2001; 21:193.
  15. Gustofson RL, Kim N, Liu S, Stratton P. Endometriosis and the appendix: a case series and comprehensive review of the literature. Fertil Steril 2006; 86:298.
  16. Jenkins S, Olive DL, Haney AF. Endometriosis: pathogenetic implications of the anatomic distribution. Obstet Gynecol 1986; 67:335.
  17. Audebert A, Petousis S, Margioula-Siarkou C, et al. Anatomic distribution of endometriosis: A reappraisal based on series of 1101 patients. Eur J Obstet Gynecol Reprod Biol 2018; 230:36.
  18. Victory R, Diamond MP, Johns DA. Villar's nodule: a case report and systematic literature review of endometriosis externa of the umbilicus. J Minim Invasive Gynecol 2007; 14:23.
  19. Jaime TJ, Jaime TJ, Ormiga P, et al. Umbilical endometriosis: report of a case and its dermoscopic features. An Bras Dermatol 2013; 88:121.
  20. Lee HJ, Park YM, Jee BC, et al. Various anatomic locations of surgically proven endometriosis: A single-center experience. Obstet Gynecol Sci 2015; 58:53.
  21. Minaglia S, Mishell DR Jr, Ballard CA. Incisional endometriomas after Cesarean section: a case series. J Reprod Med 2007; 52:630.
  22. Horton JD, Dezee KJ, Ahnfeldt EP, Wagner M. Abdominal wall endometriosis: a surgeon's perspective and review of 445 cases. Am J Surg 2008; 196:207.
  23. Morales Martínez C, Tejuca Somoano S. Abdominal wall endometriosis. Am J Obstet Gynecol 2017; 217:701.
  24. Canlorbe G, Laas E, Cortez A, Daraï E. Spontaneous hymeneal endometriosis: a rare cause of dyspareunia. BMJ Case Rep 2014; 2014.
  25. Redwine DB. Diaphragmatic endometriosis: diagnosis, surgical management, and long-term results of treatment. Fertil Steril 2002; 77:288.
  26. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817.
  27. Management of endometriosis in the presence of pelvic pain. The American Fertility Society. Fertil Steril 1993; 60:952.
  28. Abrao MS, Andres MP, Miller CE, et al. AAGL 2021 Endometriosis Classification: An Anatomy-based Surgical Complexity Score. J Minim Invasive Gynecol 2021; 28:1941.
  29. Keckstein J, Saridogan E, Ulrich UA, et al. The #Enzian classification: A comprehensive non-invasive and surgical description system for endometriosis. Acta Obstet Gynecol Scand 2021; 100:1165.
  30. Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010; 362:2389.
  31. Rahmioglu N, Nyholt DR, Morris AP, et al. Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. Hum Reprod Update 2014; 20:702.
  32. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med 2017; 376:1835.
  33. Bulun SE, Wan Y, Matei D. Epithelial Mutations in Endometriosis: Link to Ovarian Cancer. Endocrinology 2019; 160:626.
  34. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927; 14:422.
  35. Olive DL, Henderson DY. Endometriosis and mullerian anomalies. Obstet Gynecol 1987; 69:412.
  36. Dovey S, Sanfilippo J. Endometriosis and the adolescent. Clin Obstet Gynecol 2010; 53:420.
  37. Halme J, Hammond MG, Hulka JF, et al. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 1984; 64:151.
  38. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012; 98:511.
  39. Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. Stem Cells 2007; 25:2082.
  40. Longo LD. Classic pages in obstetrics and gynecology. Aberrant portions of the müllerian duct found in an ovary: William Wood Russell Johns Hopkins Hospital Bulletin, vol. 10, pp. 8--10, 1899. Am J Obstet Gynecol 1979; 134:225.
  41. JAVERT CT. The spread of benign and malignant endometrium in the lymphatic system with a note on coexisting vascular involvement. Am J Obstet Gynecol 1952; 64:780.
  42. Halban, J. Hysteroadenosis metastica. Wien Klin Wochenschr 1924; 37:1205.
  43. Gruenwald P. Origin of endometriosis from the mesenchyme of the celomic walls. Am J Obstet Gynecol 1942; 44:470.
  44. Meyer, R. Uber entzundliche neterope epithelwucherungen im weiblichen Genetalg ebiet und uber eine bis in die Wurzel des Mesocolon ausgedehnte benigne Wucherung des Dar mepithel. Virch Arch Pathol Anat 1909; 195:487.
  45. Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol 1987; 70:115.
  46. Dmowski WP, Braun D, Gebel H. Endometriosis: genetic and immunologic aspects. Prog Clin Biol Res 1990; 323:99.
  47. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76:223.
  48. Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertil Steril 2005; 83:758.
  49. Brosens I, Puttemans P, Benagiano G. Endometriosis: a life cycle approach? Am J Obstet Gynecol 2013; 209:307.
  50. Oliveira FR, Dela Cruz C, Del Puerto HL, et al. Stem cells: are they the answer to the puzzling etiology of endometriosis? Histol Histopathol 2012; 27:23.
  51. Figueira PG, Abrão MS, Krikun G, Taylor HS. Stem cells in endometrium and their role in the pathogenesis of endometriosis. Ann N Y Acad Sci 2011; 1221:10.
  52. Dekker J, Hooijer I, Ket JCF, et al. Neonatal Uterine Bleedings: An Ignored Sign but a Possible Cause of Early-Onset Endometriosis - A Systematic Review. Biomed Hub 2021; 6:6.
  53. Brosens I, Benagiano G. Is neonatal uterine bleeding involved in the pathogenesis of endometriosis as a source of stem cells? Fertil Steril 2013; 100:622.
  54. Anaf V, Simon P, El Nakadi I, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000; 15:1744.
  55. Wang G, Tokushige N, Markham R, Fraser IS. Rich innervation of deep infiltrating endometriosis. Hum Reprod 2009; 24:827.
  56. Tran LV, Tokushige N, Berbic M, et al. Macrophages and nerve fibres in peritoneal endometriosis. Hum Reprod 2009; 24:835.
  57. Matsuzaki S, Darcha C. Involvement of the Wnt/β-catenin signaling pathway in the cellular and molecular mechanisms of fibrosis in endometriosis. PLoS One 2013; 8:e76808.
  58. McKinnon BD, Bertschi D, Bersinger NA, Mueller MD. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab 2015; 26:1.
  59. Mechsner S, Kaiser A, Kopf A, et al. A pilot study to evaluate the clinical relevance of endometriosis-associated nerve fibers in peritoneal endometriotic lesions. Fertil Steril 2009; 92:1856.
  60. Arnold J, Barcena de Arellano ML, Rüster C, et al. Imbalance between sympathetic and sensory innervation in peritoneal endometriosis. Brain Behav Immun 2012; 26:132.
  61. Arnold J, Vercellino GF, Chiantera V, et al. Neuroimmunomodulatory alterations in non-lesional peritoneum close to peritoneal endometriosis. Neuroimmunomodulation 2013; 20:9.
  62. Liang Y, Yao S. Potential role of estrogen in maintaining the imbalanced sympathetic and sensory innervation in endometriosis. Mol Cell Endocrinol 2016; 424:42.
  63. Wheeler MA, Heffner DL, Kim S, et al. TNF-α/TNFR1 signaling is required for the development and function of primary nociceptors. Neuron 2014; 82:587.
  64. As-Sanie S, Harris RE, Napadow V, et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain 2012; 153:1006.
  65. Adamson GD, Kennedy S, Hummelshoj L. Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation. J Endometriosis 2010; :3.
  66. Soliman AM, Surrey E, Bonafede M, et al. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States. Adv Ther 2018; 35:408.
  67. Shafrir AL, Farland LV, Shah DK, et al. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol 2018; 51:1.
  68. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014; 348:g1752.
  69. Sangi-Haghpeykar H, Poindexter AN 3rd. Epidemiology of endometriosis among parous women. Obstet Gynecol 1995; 85:983.
  70. Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38:667.
  71. Kirshon B, Poindexter AN 3rd. Contraception: a risk factor for endometriosis. Obstet Gynecol 1988; 71:829.
  72. Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991; 6:544.
  73. Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--Part 1. BJOG 2008; 115:1382.
  74. Mowers EL, Lim CS, Skinner B, et al. Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain. Obstet Gynecol 2016; 127:1045.
  75. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997; 24:235.
  76. Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med 1982; 27:156.
  77. Goldstein DP, deCholnoky C, Emans SJ, Leventhal JM. Laparoscopy in the diagnosis and management of pelvic pain in adolescents. J Reprod Med 1980; 24:251.
  78. Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 1996; 9:125.
  79. Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199.
  80. Falcone T, Flyckt R. Clinical Management of Endometriosis. Obstet Gynecol 2018; 131:557.
  81. Hediger ML, Hartnett HJ, Louis GM. Association of endometriosis with body size and figure. Fertil Steril 2005; 84:1366.
  82. Sinaii N, Plumb K, Cotton L, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril 2008; 89:538.
  83. Treloar SA, Bell TA, Nagle CM, et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 2010; 202:534.e1.
  84. Nnoaham KE, Webster P, Kumbang J, et al. Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies. Fertil Steril 2012; 98:702.
  85. Missmer SA, Hankinson SE, Spiegelman D, et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004; 104:965.
  86. Missmer SA, Hankinson SE, Spiegelman D, et al. In utero exposures and the incidence of endometriosis. Fertil Steril 2004; 82:1501.
  87. Benagiano G, Brosens I. In utero exposure and endometriosis. J Matern Fetal Neonatal Med 2014; 27:303.
  88. Farland LV, Missmer SA, Bijon A, et al. Associations among body size across the life course, adult height and endometriosis. Hum Reprod 2017; 32:1732.
  89. Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.
  90. Parazzini F, Cipriani S, Bianchi S, et al. Risk factors for deep endometriosis: a comparison with pelvic and ovarian endometriosis. Fertil Steril 2008; 90:174.
  91. Farland LV, Eliassen AH, Tamimi RM, et al. History of breast feeding and risk of incident endometriosis: prospective cohort study. BMJ 2017; 358:j3778.
  92. Sirohi D, Freedman S, Freedman L, et al. Patient experiences of being advised by a healthcare professional to get pregnant to manage or treat endometriosis: a cross-sectional study. BMC Womens Health 2023; 23:638.
  93. Moen MH, Muus KM. Endometriosis in pregnant and non-pregnant women at tubal sterilization. Hum Reprod 1991; 6:699.
  94. Pisanu A, Deplano D, Angioni S, et al. Rectal perforation from endometriosis in pregnancy: case report and literature review. World J Gastroenterol 2010; 16:648.
  95. Brosens IA, Fusi L, Brosens JJ. Endometriosis is a risk factor for spontaneous hemoperitoneum during pregnancy. Fertil Steril 2009; 92:1243.
  96. Brosens IA, Lier MC, Mijatovic V, et al. Severe spontaneous hemoperitoneum in pregnancy may be linked to in vitro fertilization in patients with endometriosis: a systematic review. Fertil Steril 2016; 106:692.
  97. Lier M, Malik RF, van Waesberghe J, et al. Spontaneous haemoperitoneum in pregnancy and endometriosis: a case series. BJOG 2017; 124:306.
  98. Lier MCI, Malik RF, Ket JCF, et al. Spontaneous hemoperitoneum in pregnancy (SHiP) and endometriosis - A systematic review of the recent literature. Eur J Obstet Gynecol Reprod Biol 2017; 219:57.
  99. Chiodo I, Somigliana E, Dousset B, Chapron C. Urohemoperitoneum during pregnancy with consequent fetal death in a patient with deep endometriosis. J Minim Invasive Gynecol 2008; 15:202.
  100. Leone Roberti Maggiore U, Remorgida V, Sala P, et al. Spontaneous Uroperitoneum and Preterm Delivery in a Patient With Bladder Endometriosis. J Minim Invasive Gynecol 2015; 22:923.
  101. Faucheron JL, Pasquier D, Voirin D. Endometriosis of the vermiform appendix as an exceptional cause of acute perforated appendicitis during pregnancy. Colorectal Dis 2008; 10:518.
  102. Murphy SJ, Kaur A, Wullschleger ME. Endometrial decidualization: a rare cause of acute appendicitis during pregnancy. J Surg Case Rep 2016; 2016.
  103. Leone Roberti Maggiore U, Ferrero S, Mangili G, et al. A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes. Hum Reprod Update 2016; 22:70.
  104. Glavind MT, Forman A, Arendt LH, et al. Endometriosis and pregnancy complications: a Danish cohort study. Fertil Steril 2017; 107:160.
  105. Saraswat L, Ayansina DT, Cooper KG, et al. Pregnancy outcomes in women with endometriosis: a national record linkage study. BJOG 2017; 124:444.
  106. Stephansson O, Kieler H, Granath F, Falconer H. Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. Hum Reprod 2009; 24:2341.
  107. Fernando S, Breheny S, Jaques AM, et al. Preterm birth, ovarian endometriomata, and assisted reproduction technologies. Fertil Steril 2009; 91:325.
  108. Santulli P, Marcellin L, Menard S, et al. Increased rate of spontaneous miscarriages in endometriosis-affected women. Hum Reprod 2016; 31:1014.
  109. Exacoustos C, Lauriola I, Lazzeri L, et al. Complications during pregnancy and delivery in women with untreated rectovaginal deep infiltrating endometriosis. Fertil Steril 2016; 106:1129.
  110. Bruun MR, Arendt LH, Forman A, Ramlau-Hansen CH. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:1073.
  111. Farland LV, Stern JE, Liu CL, et al. Pregnancy outcomes among women with endometriosis and fibroids: registry linkage study in Massachusetts. Am J Obstet Gynecol 2022; 226:829.e1.
  112. Marcellin L, Goffinet F, Azria E, et al. Association Between Endometriosis Phenotype and Preterm Birth in France. JAMA Netw Open 2022; 5:e2147788.
  113. Lalani S, Choudhry AJ, Firth B, et al. Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. Hum Reprod 2018; 33:1854.
  114. Liu ZZ, Tang SJ, Chen X, et al. Effects of endometriosis on pregnancy outcomes in Fujian province. Eur Rev Med Pharmacol Sci 2023; 27:10968.
  115. Lafleur N, Wei SQ, Bilodeau-Bertrand M, Auger N. Association of Endometriosis and Severe Maternal Morbidity. Obstet Gynecol 2022; 140:1008.
  116. Matalliotakis I, Cakmak H, Dermitzaki D, et al. Increased rate of endometriosis and spontaneous abortion in an in vitro fertilization program: no correlation with epidemiological factors. Gynecol Endocrinol 2008; 24:194.
  117. Farland LV, Prescott J, Sasamoto N, et al. Endometriosis and Risk of Adverse Pregnancy Outcomes. Obstet Gynecol 2019; 134:527.
  118. Boje AD, Egerup P, Westergaard D, et al. Endometriosis is associated with pregnancy loss: a nationwide historical cohort study. Fertil Steril 2023; 119:826.
  119. Hadfield RM, Lain SJ, Raynes-Greenow CH, et al. Is there an association between endometriosis and the risk of pre-eclampsia? A population based study. Hum Reprod 2009; 24:2348.
  120. Brosens IA, De Sutter P, Hamerlynck T, et al. Endometriosis is associated with a decreased risk of pre-eclampsia. Hum Reprod 2007; 22:1725.
  121. HENRIKSEN E. Endometriosis. Am J Surg 1955; 90:331.
  122. Ranney B. Endometriosis. 3. Complete operations. Reasons, sequelae, treatment. Am J Obstet Gynecol 1971; 109:1137.
  123. Punnonen R, Klemi PJ, Nikkanen V. Postmenopausal endometriosis. Eur J Obstet Gynecol Reprod Biol 1980; 11:195.
  124. ESHRE Guideline Endometriosis. European Society of Human Reproduction and Embryology. 2022. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline (Accessed on February 18, 2022).
  125. Morotti M, Remorgida V, Venturini PL, Ferrero S. Endometriosis in menopause: a single institution experience. Arch Gynecol Obstet 2012; 286:1571.
  126. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006; 12:49.
  127. Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996; 81:174.
  128. Klenov VE, Potretzke TA, Sehn JK, Thaker PH. Postmenopausal Invasive Endometriosis Requiring Supralevator Pelvic Exenteration. Obstet Gynecol 2015; 126:1215.
  129. Polyzos NP, Fatemi HM, Zavos A, et al. Aromatase inhibitors in post-menopausal endometriosis. Reprod Biol Endocrinol 2011; 9:90.
  130. Rotenberg O, Kuo DYS, Goldberg GL. Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review. Climacteric 2022; 25:235.
  131. Saavalainen L, Lassus H, But A, et al. Risk of Gynecologic Cancer According to the Type of Endometriosis. Obstet Gynecol 2018; 131:1095.
  132. Oxholm D, Knudsen UB, Kryger-Baggesen N, Ravn P. Postmenopausal endometriosis. Acta Obstet Gynecol Scand 2007; 86:1158.
  133. Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18:349.
  134. Sampson JA. Endometrial carcinoma of the ovary asrising in endometrial tissue in that organ. Arch Surg 1925; 10:1.
  135. Grandi G, Toss A, Cortesi L, et al. The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life. Biomed Res Int 2015; 2015:751571.
  136. Somigliana E, Vigano' P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101:331.
  137. Melin A, Sparén P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007; 22:3021.
  138. Saavalainen L, Lassus H, But A, et al. A Nationwide Cohort Study on the risk of non-gynecological cancers in women with surgically verified endometriosis. Int J Cancer 2018; 143:2725.
  139. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13:385.
  140. Erzen M, Rakar S, Klancnik B, Syrjänen K. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001; 83:100.
  141. Steed H, Chapman W, Laframboise S. Endometriosis-associated ovarian cancer: a clinicopathologic review. J Obstet Gynaecol Can 2004; 26:709.
  142. Orezzoli JP, Russell AH, Oliva E, et al. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 2008; 110:336.
  143. Melo AS, Rosa-e-Silva JC, Rosa-e-Silva AC, et al. Unfavorable lipid profile in women with endometriosis. Fertil Steril 2010; 93:2433.
  144. Verit FF, Erel O, Celik N. Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease. Hum Reprod 2008; 23:100.
  145. Santoro L, D'Onofrio F, Campo S, et al. Endothelial dysfunction but not increased carotid intima-media thickness in young European women with endometriosis. Hum Reprod 2012; 27:1320.
  146. Mu F, Rich-Edwards J, Rimm EB, et al. Endometriosis and Risk of Coronary Heart Disease. Circ Cardiovasc Qual Outcomes 2016; 9:257.
  147. Okoth K, Wang J, Zemedikun D, et al. Risk of cardiovascular outcomes among women with endometriosis in the United Kingdom: a retrospective matched cohort study. BJOG 2021; 128:1598.
  148. Zheng M, Zheng S. Endometriosis Increases the Risk of Stroke: A Mendelian Randomization Study. Stroke 2023; 54:e30.
  149. Farland LV, Degnan WJ 3rd, Bell ML, et al. Laparoscopically Confirmed Endometriosis and Risk of Incident Stroke: A Prospective Cohort Study. Stroke 2022; 53:3116.
  150. van Barneveld E, Manders J, van Osch FHM, et al. Depression, Anxiety, and Correlating Factors in Endometriosis: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt) 2022; 31:219.
  151. Laganà AS, La Rosa VL, Rapisarda AMC, et al. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Womens Health 2017; 9:323.
  152. Facchin F, Barbara G, Saita E, et al. Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. J Psychosom Obstet Gynaecol 2015; 36:135.
  153. Adewuyi EO, Mehta D, Sapkota Y, et al. Genetic analysis of endometriosis and depression identifies shared loci and implicates causal links with gastric mucosa abnormality. Hum Genet 2021; 140:529.
  154. Koller D, Pathak GA, Wendt FR, et al. Epidemiologic and Genetic Associations of Endometriosis With Depression, Anxiety, and Eating Disorders. JAMA Netw Open 2023; 6:e2251214.
Topic 7384 Version 78.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟